Qlife Holding AB, in collaboration with its partner Hipro Biotechnology, is making significant strides in the Chinese market with its Egoo Health platform. Recent updates highlight promising clinical data, expansion into new biomarker testing, and preparations for local production of the Egoo Analyzer.
Clinical Success of Egoo CRP in China
Hipro Biotechnology has completed an initial clinical study of Egoo CRP with excellent results. The final phase of the clinical study is anticipated to conclude in the first half of 2025, paving the way for regulatory filings in China. This positions the Egoo Health platform to serve both home-hospital and pharmacy markets in China, addressing a critical need for accessible and accurate point-of-care diagnostics.
Expansion of Biomarker Testing
Hipro Biotechnology is actively integrating additional biomarker assays into the Egoo Health platform. The focus is on key disease areas, including heart failure, chronic kidney disease, diabetes, and conditions related to inflammation and infection. These efforts will generate comprehensive technical data packages to support clinical studies and regulatory submissions.
Qlife plans to leverage these data packages for regulatory filings outside of China, including in the EU, UK, USA, and other regions. The admissibility of Chinese data in these markets is expected to yield significant cost savings by reducing or eliminating the need for redundant clinical studies.
Local Production of Egoo Analyzer
To ensure a competitive cost structure, Hipro Biotechnology is establishing local production for the Egoo Health platform, including the Egoo Analyzer. The Egoo Analyzer is a complex medical device requiring a robust production infrastructure. Local production is deemed essential to achieve the necessary competitive cost of goods sold (COGS) for success in the Chinese market.
Qlife anticipates that Hipro Biotechnology's management of production will not only benefit the Chinese market but also enable a competitive cost structure for international markets, which Qlife aims to address through future strategic partnerships. Hipro Biotechnology has sales to more than 14,000 hospitals in China.
